First Clinical Study of SeptAlign™ Implant Demonstrates Safety and Efficacy in Treating Nasal Septal Deviation While Preserving Cartilage
Prospective Zephyr Study Confirms Durable Symptom Relief and Safety Profile of SeptAlign™ Implant at One Year
Spirair Receives FDA Clearance for SeptAlign, the First and Only Minimally Invasive Therapy for Mechanical Correction of Nasal Septal Deviation
New therapy provides a minimally invasive option for ENTs to straighten minor deviations in septal cartilage and help address nasal airway obstruction.
Spirair Announces Appointment of Chief Executive Officer
Spirair Announces Appointment of Chief Executive Officer Spirair is entering its next stage of growth as it prepares for commercialization.